QDEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
QuidelOrtho Corp (QDEL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is experiencing a bearish trend with declining revenue and mixed analyst ratings. While insider buying and a low put-call ratio indicate some positive sentiment, the lack of strong financial performance and technical signals suggests holding off on investment until clearer signs of recovery emerge.
The stock is in a bearish trend with MACD below 0 and negatively contracting, RSI at 31.316 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 20.05, and resistance is at 23.72. The stock is trading near its support level, but no clear reversal signals are present.
Insiders are buying significantly, with a 2578.44% increase in buying activity over the last month. Director Matthew Strobeck recently purchased 10,000 shares, showing confidence in the company's long-term growth.
The company reported a 1.89% YoY revenue decline for Q4 FY 2025, marking the third consecutive year of revenue decline. CFO Joseph M. Busky's retirement adds uncertainty to the company's leadership amid ongoing challenges. Analysts have mixed ratings, with some downgrading price targets and maintaining neutral or underweight ratings.
In Q4 FY 2025, revenue declined by 1.89% YoY, marking the third consecutive year of revenue decline. In Q3 FY 2025, revenue dropped by 3.74% YoY, while net income increased significantly to -733 million, up 3583.42% YoY, driven by cost adjustments. EPS also improved to -10.78, up 3493.33% YoY, but gross margin slightly declined to 41.13%.
Analysts have mixed views. Citi and JPMorgan raised price targets to $30 and $25, respectively, but maintain Neutral and Underweight ratings. UBS lowered its price target to $30 from $35, citing mixed guidance and focusing on free cash flow. Overall, analysts are cautious, with no strong buy recommendations.
